Hyperhomocysteinemia and retinal vascular occlusive disease

European Journal of Ophthalmology

Volumn 12, Issue 6, 2002, Pages 495-500

  Abu El Asrar, A M ^a,b   Abdel Gader, A G M ^a   Al Amro, S A ^a   Al Attas, O S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Hyperhomocysteinemia; Retinal artery occlusion; Retinal vein occlusion; Risk factors

Indexed keywords

HOMOCYSTEINE;

ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROCHEMICAL ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA ARTERY OCCLUSION; RETINA BLOOD VESSEL OCCLUSION; RISK FACTOR; ADOLESCENT; ADULT; AGED; BLOOD; CHILD; COMPARATIVE STUDY; MIDDLE AGED; PROSPECTIVE STUDY; RETINA VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL ARTERY OCCLUSION; RETINAL VEIN OCCLUSION; RISK FACTORS;

EID: 0036879456     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210201200608     Document Type: Article

References (33)

1. Townend J, O'Sullivan J, Wilde JT. Hyperhomocysteinemia and vascular disease. Blood Rev 1998; 12: 23-34.
2. Hankey G, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-13.
3. Guba SC, Fink LM, Fonseca V. Hyperhomocysteinemia: an emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996; 105: 709-22.
4. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
5. Mudd SU, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
6. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA 1995; 274: 1049-57.
7. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
8. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
9. Gupta A, Moustapha A, Jacobsen DW, et al. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998; 65: 544-50.
10. Stehouwer CDA, Weijenberg MP, Van den Berg M, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998; 18: 1895-901.
11. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-9.
12. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta analysis. Thromb Haemost 1998; 80: 874-7.
13. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb Vasc Biol 1994; 14: 1080-3.
14. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
15. Gemmati D, Previati M, Senino ML, et al. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Arterioscler Thromb Vasc Biol 1999; 19: 1761-7.
16. Martin SC, Hilton AC, Bartlett WA, Jones AF. Plasma total homocysteine measurement by ion-paired reversed-phase HPLC with electrochemical detection. Biomed Chromatogr 1998; 12: 1-2.
17. Wenzler EM, Rademakers AJJM, Boers GHJ, Cruysberg JRM, Webers CAB, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993; 115: 162-7.
18. Martin SC, Pauz S, Marr JE, Martin N, Jones AF, Dodson PM. Plasma total homocysteine and retinal vascular disease. Eye 2000; 14: 590-3.
19. Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000; 129: 640-4.
20. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000; 84: 154-7.
21. Pianka P, Almog Y, Man O, Goldstein M, Sela B, Lowenstein A. Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000; 107: 1588-92.
22. Cahill M, Karabatzaki M, Donoghue C, et al. Thermolabile MTHFR genotype and retinal vascular occlusive disease. Br J Ophthalmol 2001; 85: 88-90.
23. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocyst(e)inemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy. Br J Ophthalmol 2001; 85: 803-6.
24. Hoogeveen EK, Kostense PJ, Eysink PED, et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus. The Hoorn Study. Arch Intern Med 2000; 160: 2984-90.
25. de Jong SC, Van den Berg M, Rauwerda JA, Stehouwer CD. Hyperhomocysteinemia and atherothrombotic disease. Semin Thromb Hemost 1998; 24: 381-5.
26. Loewenstein A, Goldstein M, Winder A, Lazar M, Elder A. Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. Ophthalmology 1991; 106: 1817-20.
27. Van derGriend R, Haas FJ, Biesma DH, Duran N, Meuwissen OJ, Banga JD. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinemia in patients with premature arterial disease and their relatives. Atherosclerosis 1999; 143: 177-83.
28. den Heijer M, Brouwer IA, Bos GM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 356-61.
29. Kluijtmans LA, Boers GH, Kraus JP, et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet 1999; 65: 59-67.
30. Hayreh SS, Zimmermann MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117: 429-41.
31. Dodson PM, Kritzinger EE. Medical cardiovascular treatment trials: relevant to medical ophthalmology in 1997? Eye 1997; 11: 3-11.
32. Elman MJ, Bhatt AK, Quinlan PM, Engen C. The risk of systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97: 1543-8.
33. Mansour AM, Walsh JB, Henkind P. Mortality and morbidity in patients with central retinal vein occlusion. Ophthalmologica 1992; 204: 199-203.